Twist Bioscience (NASDAQ:TWST) CEO Sells $279,181.63 in Stock

by · The Cerbat Gem

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CEO Emily Leproust sold 1,687 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $165.49, for a total transaction of $279,181.63. Following the transaction, the chief executive officer directly owned 618,902 shares of the company’s stock, valued at $102,422,091.98. This represents a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Trading Down 0.7%

NASDAQ:TWST opened at $182.83 on Friday. The stock has a fifty day moving average price of $126.89 and a two-hundred day moving average price of $87.13. The stock has a market capitalization of $11.47 billion, a price-to-earnings ratio of -82.36 and a beta of 2.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $186.20.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same quarter in the previous year, the business posted $0.33 earnings per share. Twist Bioscience’s revenue was up 23.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. QRG Capital Management Inc. acquired a new stake in shares of Twist Bioscience during the second quarter worth approximately $277,000. Engineers Gate Manager LP bought a new stake in shares of Twist Bioscience in the second quarter worth $3,333,000. Integrated Wealth Concepts LLC acquired a new stake in Twist Bioscience in the second quarter valued at $99,000. Allworth Financial LP raised its holdings in Twist Bioscience by 54.9% in the second quarter. Allworth Financial LP now owns 601 shares of the company’s stock valued at $62,000 after acquiring an additional 213 shares in the last quarter. Finally, Nykredit A S bought a new position in Twist Bioscience during the 2nd quarter valued at $283,000.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TWST. Robert W. Baird increased their target price on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Canaccord Genuity Group upped their price objective on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. UBS Group started coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective on the stock. Leerink Partners boosted their target price on shares of Twist Bioscience from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Thursday, September 17th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus target price of $103.00.

Read Our Latest Stock Analysis on TWST

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.

See Also